Navigation Links
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Date:11/8/2011

not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON in the United States, if approved, or in certain European countries being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. Each company's results may also be affected by risks inherent in the termination of their collaboration and the risk that Amylin may not have the financial resources to meet the obligations mentioned in this press release. Amylin's results may also be affected by risks associated with its assumption of full responsibilities for the worldwide development and commercialization of exenatide, including the risks that the transition of Lilly's collaboration responsibilities to Amylin will not proceed according to plan, and risks that Amylin's future efforts to further develop and commercialize the exenatide franchise, including any efforts to re-partner the development and commercialization of exenatide outside the United States, may not produce the results Amylin expects. Lilly's results may be affected by the risks inherent in the development of Lilly's pipeline, and there can be no guarantees that pipeline products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
2. Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership
3. Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
4. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
5. Lilly Reports Third-Quarter 2011 Results
6. Lilly Declares Fourth-Quarter 2011 Dividend
7. Lilly Announces Changes in Senior Management
8. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
9. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
10. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
11. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... REDWOOD CITY, Calif. , May 21, 2015  Cardica, ... 20, 2015, new employee Greg Watson , the company,s ... 400,000 shares of the company,s common stock, at a per ... May 20, 2015. The stock option was granted pursuant to ... board of directors in May 2015 under Rule 5653(c)(4) of ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Technology advances have had a profound effect on ... a constantly evolving communication environment, companies need to continuously ... It is challenging, however, to gauge the effectiveness of ... of today,s internal and external communication options. ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the 2011 Credit Suisse Annual ... live presentation takes place on Wednesday, November 9, 2011 at ... 1:00 p.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers 2
(Date:5/25/2015)... (PRWEB) May 25, 2015 A recent report ... states 1,000 persons have died as a direct result of ... This marks a 33% rise in overdose deaths attributed to ... Baker, “This issue doesn’t care about geography. This issue doesn’t ... issue doesn’t care about class.” As the state of Mass. ...
(Date:5/25/2015)... 2015 ProDrop Light Show allows users ... light backdrops with a click of a mouse. Users have full ... all within Final Cut Pro X. , ProDrop Light Show gives ... zones, kaleidoscope and much more leaving infinite possibilities all within Final ... zones and text presets, users can apply their very own media ...
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... (PRWEB) May 25, 2015 Pacific Prime has announced ... part report looking at the cost of individual international health ... Article 2 looks at the cost of health insurance in six ... Focusing on, Hong Kong , ... the UAE , the UK , ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 For people ... and Chinese Enterokinase Industry, 2009-2019 Market Research Report would ... is an exhaustive study on the present market scenario ... insight into the growing Chinese market of this industry. ... the overall status of the manufacturers in this industry. ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... Choices ( http://www.nhs.uk ), the,digital ,front door, to the ... to see both the physical and financial cost of ... information, the interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to ... up how much you could save over,one to ten ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... suggests eating foods such as whole grains cuts risk ... -- Increased consumption of magnesium-rich foods such as whole ... which occurs when blood flow to the brain is ... the Karolinska Institute in Stockholm analyzed the diets and ...
... ALLEGAN, Mich., March 11 Perrigo Company,(Nasdaq: ... final approval,from the U.S. Food and Drug Administration (FDA) ... Foam, 0.05%., The product is a topical corticosteroid ... the scalp. Sales for the brand, Olux(R),Foam, 0.05%, were ...
... Verathon(R) is pleased to,announce a new Small Child ... instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child Mode enables ... children weighing less than 60 pounds and,standing less ... used for adult,patients. This enhanced BladderScan(R) BVI 9400 ...
... . , Malignant tumors have usually lost their ... apoptosis. Therefore, tumors are often resistant to chemotherapy or ... cells to commit suicide. , This resistance to ... numerous molecular switches regulating the self-destruction process. This is ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: